Vaxcyte Inc. (PCVX)
69.40
-1.37 (-1.94%)
At close: Mar 28, 2025, 3:59 PM
69.11
-0.42%
After-hours: Mar 28, 2025, 05:05 PM EDT
-1.94% (1D)
| Bid | 65 |
| Market Cap | 8.94B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -486.27M |
| EPS (ttm) | -3.8 |
| PE Ratio (ttm) | -18.26 |
| Forward PE | -21.19 |
| Analyst | Buy |
| Ask | 84.84 |
| Volume | 507,921 |
| Avg. Volume (20D) | 1,138,796 |
| Open | 70.84 |
| Previous Close | 70.77 |
| Day's Range | 68.38 - 71.22 |
| 52-Week Range | 58.10 - 121.06 |
| Beta | 1.02 |
About PCVX
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a co...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 12, 2020
Employees 414
Stock Exchange NASDAQ
Ticker Symbol PCVX
Website https://vaxcyte.com
Analyst Forecast
According to 9 analyst ratings, the average rating for PCVX stock is "Buy." The 12-month stock price forecast is $146.5, which is an increase of 111.10% from the latest price.
Stock Forecasts1 month ago
+3.26%
Vaxcyte shares are trading higher after the compan...
Unlock content with
Pro Subscription
4 months ago
-6.31%
Shares of vaccine stocks are trading lower After President-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.
